Very excited to announce that we’ve dosed our first patient with our latest next-gen cancer immunotherapy drug which is broadly applicable to most solid tumors! We started working on this one in 2022. It’s really cool to see how quickly a drug can go from an idea into the clinic. https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx
- 16 replies
- 12 recasts
- 73 reactions
7600 meter row rowing machine tracked. Points earned. +10 for showing up with Griv
- 7 replies
- 0 recasts
- 2 reactions
I appreciate the long term vision here, it’ll be interesting to look back on these posts 10 years from now and see if this vision comes to fruition.
- 0 replies
- 1 recast
- 3 reactions